PDA

View Full Version : UK: Huge weight gains reported by patients on prescription drugs



Binky
06-25-2007, 01:21 PM
Huge weight gains reported by patients on prescription drugs

By Roger Dobson

Thousands of people who take prescription medicines for everyday conditions are gaining large amounts of weight as an unexpected side effect, scientists have warned.

Researchers, who found that some patients were putting on up to 22lbs in a year, say that the drugs may even be contributing to the nation's rocketing obesity epidemic.

All of the patients they studied, on medication for conditions as diverse as diabetes, epilepsy, depression, high blood pressure and schizophrenia, showed evidence of weight increase.

"Given the common and long-term use of many of these drugs," said the researchers, "it is likely that they play a significant contributory role in the increasing prevalence of obesity."

A team from Glasgow University and Glasgow Royal Infirmary reviewed and analysed data on drug use by more than 25,000 people to quantify the effects of prescription drugs.

All of the drugs included in the review are used to treat chronic diseases by large numbers of people. In the UK, it is estimated that around 2.6 million people have been diagnosed with coronary heart disease, for which beta-blockers are widely prescribed. More than 400,000 people have epilepsy, and around 1.3 million people have type 1 or type 2 diabetes.

"In the light of these figures, the number of individuals in the population receiving treatment with an obesogenic drug is potentially quite high. In Scotland alone, the number of prescriptions dispensed for beta-blockers and tricyclic antidepressants between 2004 and 2005 exceeded one million and two million respectively," says the report.

With many of the drugs, weight gain was significant and rapid, according to the researchers. Just how they lead to weight gain varies, and is in some cases unknown. Some, like corticosteroids, increase appetite, while beta-adrenoceptor blockers reduce metabolic rate.

Olanzapine and clozapine, drugs used for psychiatric conditions, resulted in the most weight gain - up to 22lbs in 52 weeks. Insulin for type 2 diabetes was found to increase weight by up to 13.2lbs, while some drugs for depression added up to 8lbs, and some for high blood pressure led to gains of up to 3lbs. A heart drug added 5lbs, while some treatments for epilepsy added more than 12lbs, and some bipolar drugs led to weight gains of around 8lbs.

The researchers say that many other drugs which are being prescribed and have not been investigated may also have an effect on weight.

They also suggest that unexpected weight gain may be a reason why some people stop taking prescribed drugs: "Non-compliance with any drug therapy is a widespread problem, and around half of patients prescribed long-term medication for the management of chronic diseases do not comply fully with treatment.

"Non-compliance is reported as an issue with many of the drugs included in this review, and the weight gain associated with them may contribute to this."

In future, the scientists suggest, doctors should discuss with patients the risk of weight gain before they start treatment: "This review provides evidence of the weight gain potential of some common drugs. It is perhaps only now, in light of the present epidemic of obesity, that the negative effect on body weight is a pertinent issue. The potential of weight gain should be discussed with patients prior to the institution of therapy."

Side effects: Prescription problems

The drugs listed below are prescription medicines implicated in the new research. Each has been identified as possibly being responsible for dramatic weight gain:

Beta-blockers

Used to treat high blood pressure, abnormal heart rhythms and panic attacks. The drugs block the effects of adrenalin, slowing the heart rate.

Corticosteroids

Generally known as steroids, the drug is used to treat various conditions, from rheumatoid arthritis to stress relief after a trauma or operation.

Olanzapine

Used to treat schizophrenia and manic episodes. Is said to help the patient stay in touch with reality.

http://news.independent.co.uk/health/article2701322.ece

Thanks to reddiet for the snip:D Good info:)

lequebecfume
11-06-2008, 11:13 AM
Pfizer ends testing obesity drug on account of risk of US non-approval news

06 November 2008



Drug maker Pfizer Inc. has said it is going to put an end to testing an obesity drug on account of the risk of approval by the US being slow, expensive, and risky.

By doing so, Pfizer is following in the footsteps of other drug companies who have taken similar measures. Pfizer has decided not to put any more money into new human tests that the US Food and Drug Administration (USFDA) is likely to ask for, according to a statement by the New York-based company.

The obesity drug, known by the chemical name CP-945,598, was in the final stage of a three-stage testing process needed for market clearance by the USFDA. Reports said that analysts predicted annual sales for the drug at over $500 million.

Obesity medicines basically block the same brain receptor that makes marijuana smokers hungry.


Earlier, Sanofi-Aventis SA's drug was rejected by the FDA in June 2007. Drug manufacturer Merck & Co quit also stopped developing its version last month. Reports had said that analysts were of the opinion that annual sales of anti-obesity drugs would be in excess of $3 billion. Studies by Merck and Sanofi were reported to have found that their versions of the drug could have links to suicides and depression.

Bristol-Myers Squibb Co. is now the last major drug company to be still developing a similar medicine, Bloomberg said.

In its statement, Martin Mackay, Pfizer's president of research said, ''While confident in the safety of the compound, we believe that this is the appropriate decision based on all available information regarding this class of agents, as well as recent discussions with regulatory authorities. As part of our ongoing portfolio prioritization, we will refocus research and development resources on high-priority therapeutic areas that address an unmet medical need and have a high probability for success.''

Last month, the European Medicines Evaluation Agency (EMEA) had recommended the suspension of the anti – obesity drug rimonabant, better known by its brand name Acomplia on account of concerns that it may increase depression, sleep disorders, anxiety and aggression in some overweight or obese patients.

http://www.domain-b.com/companies/companies_p/Pfizer/20081106_obesity_drug.html